Study of adrenergic receptor disease; drug development.
The diagnosis and treatment of Adrenergic Receptor (AR) diseases has been
confounded by the variety of AR subtypes. Drs. Esbenshade and Minneman have
successfully cloned the human Alpha 1d AR subtype, which is specific for
cardiovascular tissue. This new clone will facilitate a better understanding of
cardiovascular AR disease and provide a means for developing improved
pharmaceuticals to manage the disease.
Clinicians do not always appreciate the disparate efficacy of AR receptor
pharmaceuticals. Drs. Esbenshade and Minneman have demonstrated that the binding
affinities of certain pharmaceutical compounds for different AR subtypes varies
This new cardiovascular tissue specific AR receptor permits the
identification of pharmaceutical agents that should be highly selective in the
treatment and management of cardiovascular AR related diseases.